On Wednesday, OpenAI released GPT-5.5, deploying its most advanced artificial intelligence model directly to its paid tiers. Access is immediately gated to Plus, Pro, Business, and Enterprise subscribers. The software features significant, verifiable improvements in agentic coding, computer use, and scientific research.

By locking the model behind a strict paywall, the company is enforcing a cognitive enclosure, ensuring that only capitalized institutions can deploy autonomous agents capable of independent execution. Simultaneously, the firm announced "ChatGPT for Clinicians," distributing the medical diagnostic tool entirely for free to verified U.S. medical providers. According to OpenAI, the clinical tool provides "cited answers from medical sources" to support evidence review and documentation drafting.

The dual deployment is a masterclass in market segmentation. The firm is fiercely protecting its high-value intellectual property—autonomous financial and software engineering agents—while aggressively subsidizing the automation of the clinical commons. Florida state senator Gayle Harrell recently stressed at a HIMSS26 healthcare event that regulations must ensure "decision-making power remains with clinicians." That power is rapidly shifting to the software layer. By providing free diagnostic algorithms directly to doctors, the technology sector is steadily commoditizing traditional healthcare labor, capturing the administrative margin without assuming the malpractice liability.